Proteostatic Valuation

Time to Pull Out a Napkin

The standard AMT-130 bull case is a huntingtin-lowering drug in a rare disease. Approve it, price it like Zolgensma, collect the orphan drug premium, done. That model produces a number somewhere around ~$100 per share and requires you to believe the FDA eventually does its job.

That’s probably the wrong model entirely.